Hematologic Malignancies Testing Market Report 2026

Hematologic Malignancies Testing Market Overview

• Hematologic Malignancies Testing market size has reached to $3.58 billion in 2025 • Expected to grow to $6.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.2% • Growth Driver: Increase In Cancer Diagnoses Fueling The Growth Of The Market Due To Enhanced Screening Access And Early Detection • Market Trend: Technological Innovations Enhancing Hematologic Cancer Diagnosis And Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hematologic Malignancies Testing Market?

Hematologic malignancies testing refers to the diagnostic and monitoring processes used to detect, classify, and evaluate blood, bone marrow, and lymphatic system cancers. This testing accurately identifies the malignancy type and subtype determines prognosis, guides treatment decisions, and monitors response to therapy or disease recurrence. The main test type of hematologic malignancies are complete blood count (CBC), flow cytometry, molecular testing, genetic testing and other test types. A complete blood count (CBC) is a blood test that measures different components of blood, including red cells, white cells, hemoglobin, hematocrit, and platelets. The products are categorized into kits and services. The various technology include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, and other technologies. The various therapeutic indications include leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. These are used by various end-users such as hospitals, diagnostic labs, academic and research institutions, and other end users.

What Is The Hematologic Malignancies Testing Market Growth Forecast?

The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $6.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, growing integration of ai-based data interpretation, expansion of companion diagnostics, rising adoption of mrd monitoring, increasing investments in advanced diagnostic technologies. Major trends in the forecast period include increasing adoption of ngs-based diagnostic testing, rising use of flow cytometry for mrd detection, growing integration of molecular and genetic assays, expansion of personalized diagnostic profiling, enhanced focus on early and accurate subtyping.

Global Hematologic Malignancies Testing Market Segmentation

1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type 2) By Product: Kits, Services 3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology 4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication 5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users Subsegments: 1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH) 2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis 3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis 4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis 5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests

What Is The Driver Of The Hematologic Malignancies Testing Market?

The rising number of cancer diagnoses is expected to propel the growth of the hematologic malignancies testing market going forward. Cancer diagnoses refer to the process of identifying the presence, type, and stage of cancer in a patient using various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rising number of cancer diagnoses is due to improved access to screening programs and heightened public awareness, resulting in earlier detection. Hematologic malignancies testing is helpful in cancer diagnoses by enabling early detection, accurate classification, and monitoring of blood-related cancers, ultimately guiding targeted treatment decisions and improving patient outcomes. For instance, according to American Cancer Society, an US-based a nonprofit organization, in 2024, over 2 million new cancer cases are diagnosed in the US, a 4% increase from previous years. Therefore, the rising number of cancer diagnoses drives growth in the hematologic malignancies testing industry.

Key Players In The Global Hematologic Malignancies Testing Market

Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings

Global Hematologic Malignancies Testing Market Trends and Insights

Major companies operating in the hematologic malignancies testing market are focusing on developing innovative diagnostic approaches, such as rapid molecular profiling, to provide healthcare providers with precise and timely diagnostic tools that enhance early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic approach that analyzes a patient's genetic makeup to identify mutations and variations, enabling faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers such as leukemia, lymphoma, and multiple myeloma more accurately and quickly. The test identifies mutations in hundreds of genes in under 72 hours, significantly improving the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.

What Are Latest Mergers And Acquisitions In The Hematologic Malignancies Testing Market?

In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology company that offers hematologic malignancies testing partnered with NeoGenomics Laboratories, Inc. to personalized disease monitoring for blood cancer patients. Through this partnership, Adaptive Biotechnologies and NeoGenomics aim to expand access to precise minimal residual disease monitoring in blood cancers by integrating the clonoSEQ test into NeoGenomics’ diagnostic services, enhancing treatment decisions and disease tracking. NeoGenomics Laboratories Inc. is a US-based public, high-complexity clinical laboratory company that specializes in cancer genetics diagnostic testing.

Regional Outlook

North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hematologic Malignancies Testing Market?

The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hematologic Malignancies Testing Market Report 2026?

The hematologic malignancies testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.